BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
117 results:

  • 1. Anti-Tumor Activity and Mechanism of Silibinin Based on Network Pharmacology and Experimental Verification.
    Li P; Wang D; Yang X; Liu C; Li X; Zhang X; Liu K; Zhang Y; Zhang M; Wang C; Wang R
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675723
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Extensive Hepatic Infarction due to Polycythemia Vera.
    Furukawa K; Urano F; Okamura S; Kawashima H
    J Gastrointestin Liver Dis; 2024 Mar; 33(1):18. PubMed ID: 38554424
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/jak2/STAT3 signal pathway.
    Shi X; Lai Y; Liu W; Zhang X; Cang Y
    Biochem Biophys Res Commun; 2024 Apr; 706():149758. PubMed ID: 38484571
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma.
    Yu H; Sun F; Xu Y; Yang H; Tian C; Li C; Kang Y; Hao L; Yang P
    Hum Gene Ther; 2024 Mar; 35(5-6):177-191. PubMed ID: 38386514
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting C21orf58 is a Novel treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of jak2/C21orf58/STAT3 Complex.
    Jiang H; Wang Y; Wen D; Yu R; Esa SS; Lv K; Feng Q; Liu J; Li F; He L; Di X; Zhang S
    Adv Sci (Weinh); 2024 Apr; 11(15):e2306623. PubMed ID: 38342622
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Bacterial heat shock protein: A new crosstalk between T lymphocyte and macrophage via jak2/STAT1 pathway in bloodstream infection.
    Yin S; Peng Y; Lin Y; Wu H; Wang B; Wang X; Chen W; Liu T; Peng H; Li X; Xu J; Wang M
    Microbiol Res; 2024 May; 282():127626. PubMed ID: 38330817
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Cepharanthine suppresses proliferation and metastasis and enhances apoptosis by regulating jak2/Stat3 pathway in hepatocellular carcinoma.
    Liang Y; Li J; Xu H; Pang M; Hu C; Weng X; Xie W
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):94-100. PubMed ID: 38279472
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
    Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
    Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. SOCS2 inhibits hepatoblastoma metastasis via downregulation of the jak2/STAT5 signal pathway.
    Lv Y; Xie X; Zou G; Kong M; Yang J; Chen J; Xiang B
    Sci Rep; 2023 Dec; 13(1):21814. PubMed ID: 38071211
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Astaxanthin Augmented the Anti-Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the jak2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment.
    Ren P; Tang Q; He X; Xu J; Wang Y; Xue C
    Mol Nutr Food Res; 2024 Jan; 68(2):e2300569. PubMed ID: 38059808
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. METTL3 facilitates stemness properties and tumorigenicity of cancer stem cells in hepatocellular carcinoma through the SOCS3/jak2/STAT3 signaling pathway.
    Hu J; Chen K; Hong F; Gao G; Dai X; Yin H
    Cancer Gene Ther; 2024 Feb; 31(2):228-236. PubMed ID: 38030810
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.
    Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E
    Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/jak2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
    Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
    Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM; Üremiş N; Türköz Y
    Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Furanocoumarin Notopterol: Inhibition of Hepatocellular Carcinogenesis through Suppression of cancer Stemness Signaling and Induction of Oxidative Stress-Associated Cell Death.
    Huang TY; Yang CK; Chen MY; Yadav VK; Fong IH; Yeh CT; Cherng YG
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299411
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Acute graft-versus-host disease.
    Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
    Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating jak2/STAT3 Pathway.
    Zhu WT; Zeng XF; Yang H; Jia ML; Zhang W; Liu W; Liu SY
    Int J Nanomedicine; 2023; 18():2677-2691. PubMed ID: 37228445
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
    Hong L; Aminu M; Li S; Lu X; Petranovic M; Saad MB; Chen P; Qin K; Varghese S; Rinsurongkawong W; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Gandhi SJ; Lin SH; Lee PP; Carter BW; Wu CC; Antonoff MB; Sepesi B; Lewis J; Gibbons DL; Vaporciyan AA; Le X; Jack Lee J; Roy-Chowdhuri S; Routbort MJ; Gainor JF; Heymach JV; Lou Y; Wu J; Zhang J; Vokes NI
    Nat Commun; 2023 Feb; 14(1):695. PubMed ID: 36755027
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the jak2/STAT3 signaling pathway.
    Ma X; Xu W; Jin X; Mu H; Wang Z; Hua Y; Cai Z; Zhang T
    Eur J Pharmacol; 2023 Mar; 942():175529. PubMed ID: 36690054
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Portal vein thrombosis as the presenting manifestation of jak2 positive myeloproliferative neoplasm.
    Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
    Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.